Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

[Image: see text] Hyperactivation of mTOR kinase by mutations in the PI3K/mTOR pathway or by crosstalk with other mutant cancer drivers, such as RAS, is a feature of many tumors. Multiple allosteric inhibitors of mTORC1 and orthosteric dual inhibitors of mTORC1 and mTORC2 have been developed as anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnett, G. Leslie, Yang, Yu C., Aggen, James B., Pitzen, Jennifer, Gliedt, Micah K., Semko, Chris M., Marquez, Abby, Evans, James W., Wang, Gang, Won, Walter S., Tomlinson, Aidan C. A., Kiss, Gert, Tzitzilonis, Christos, Thottumkara, Arun P., Cregg, James, Mellem, Kevin T., Choi, Jong S., Lee, Julie C., Zhao, Yongyuan, Lee, Bianca J., Meyerowitz, Justin G., Knox, John E., Jiang, Jingjing, Wang, Zhican, Wildes, David, Wang, Zhengping, Singh, Mallika, Smith, Jacqueline A. M., Gill, Adrian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841523/
https://www.ncbi.nlm.nih.gov/pubmed/36533617
http://dx.doi.org/10.1021/acs.jmedchem.2c01658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841523/
https://www.ncbi.nlm.nih.gov/pubmed/36533617
http://dx.doi.org/10.1021/acs.jmedchem.2c01658

Ejemplares similares